“We appreciate the recognition of this achievement, as getting new therapies with reasonable safety profiles to people who need them is our main goal,” said Dr. Seth Forman, founder of ForCare Clinical Research and ForCare Medical Group. “The ForCare Clinical Research team works very hard to get these medications to market because we realize patients are waiting for treatments. We keep in mind what it would be like if we were the patients waiting for a new medication that could heal us.”
Specifically, ForCare Clinical Research is enrolling studies for Vitiligo and Alopecia Areata. ForCare has also completed studies for Atopic Dermatitis and Hidradenitis Sippurativa.
About 200 investigative sites participated in the study, which analyzed timing and performance metrics data and the impact of clinical site staff-training by accredited organizations such as ACRP, the leader in clinical trials workforce development and certification. Participants submitted reports focused on five specific study start-up and performance metrics which, along with a myriad of other data points, were already being automatically tracked and captured.
ForCare Clinical Research is the clinical research arm of ForCare Medical Group based in Tampa, Fla. ForCare Medical Group specializes in Primary Care, Rheumatology and Dermatology. With one center on Ehrlich Rd. and a brand new state-of-the-art, 30,000-square foot facility opening soon on Florida Ave., ForCare has served those in the Tampa area for 10 years. ForCare’s physicians and staff are dedicated to providing excellent care, utilizing the most advanced technology and procedures. More information about ForCare Medical Group is available by calling 813.940.2600 and is online at www.ForCareMed.com.